News
LONDON, UK I May 12, 2025 I Leucid Bio ("Leucid" or "The Company"), a privately-held biotechnology company pursuing the development of innovative Chimeric ...
The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback